Published in Neurosci Lett on September 25, 2013
Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype. Oncotarget (2015) 0.86
Use of Animal Models in Understanding Cancer-induced Bone Pain. Cancer Growth Metastasis (2015) 0.83
Functional neural-bone marrow pathways: implications in hypertension and cardiovascular disease. Hypertension (2014) 0.81
Cytokines as Mediators of Pain-Related Process in Breast Cancer. Mediators Inflamm (2015) 0.79
Clinical and genetic factors related to cancer-induced bone pain and bone pain relief. Oncologist (2014) 0.78
Induction of thermal and mechanical hypersensitivity by parathyroid hormone-related peptide through upregulation of TRPV1 function and trafficking. Pain (2015) 0.77
The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain. Pain (2016) 0.77
Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain. Biochim Biophys Acta (2015) 0.77
Acidic microenvironment and bone pain in cancer-colonized bone. Bonekey Rep (2015) 0.75
The Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats. Front Pharmacol (2016) 0.75
Identification of capsazepine as a novel inhibitor of system xc(-) and cancer-induced bone pain. J Pain Res (2017) 0.75
Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain. Pain (2016) 0.75
The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain. Int J Mol Med (2016) 0.75
The Analgesic and Antineuroinflammatory Effect of Baicalein in Cancer-Induced Bone Pain. Evid Based Complement Alternat Med (2015) 0.75
Effect of elcatonin versus nonsteroidal anti-inflammatory medications for acute back pain in patients with osteoporotic vertebral fracture: a multiclinic randomized controlled trial. J Bone Miner Metab (2016) 0.75
Cancer-Induced Bone Pain Management Through Buddhist Beliefs. J Relig Health (2017) 0.75
Etanercept attenuates thermal and mechanical hyperalgesia induced by bone cancer. Exp Ther Med (2017) 0.75
Intratumoral acidosis fosters cancer-induced bone pain through the activation of the mesenchymal tumor-associated stroma in bone metastasis from breast carcinoma. Oncotarget (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 30.59
Osteoclast differentiation and activation. Nature (2003) 18.59
The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron (1998) 13.03
Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell (2008) 11.18
An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain (1992) 9.17
THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol (1927) 7.64
A proton-gated cation channel involved in acid-sensing. Nature (1997) 6.98
Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem (1990) 5.36
A receptor for protons in the nerve cell membrane. Neuroscience (1980) 4.70
Breakthrough pain: definition, prevalence and characteristics. Pain (1990) 3.35
Isolectin B(4)-positive and -negative nociceptors are functionally distinct. J Neurosci (1999) 3.12
The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol (2008) 3.05
Hypoxia and cancer. J Mol Med (Berl) (2007) 2.89
Management of cancer pain. Lancet (1999) 2.76
Malignant bone pain: pathophysiology and treatment. Pain (1997) 2.75
Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience (2002) 2.57
Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol (2007) 2.49
The role of glutathione in cancer. Cell Biochem Funct (2004) 2.36
Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest (2004) 2.30
Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience (2000) 2.28
A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther (2004) 2.21
Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci (1999) 2.19
Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta (2002) 2.18
Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther (2006) 2.13
Acid-sensing ion channels (ASICs): pharmacology and implication in pain. Pharmacol Ther (2010) 1.92
Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J Neurosci (2002) 1.91
Protons: small stimulants of capsaicin-sensitive sensory nerves. Trends Neurosci (1994) 1.90
Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci (2005) 1.83
Characterization of cytokine-induced hyperalgesia. Brain Res (1994) 1.78
Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One (2009) 1.72
Pancreatic neuropathy and neuropathic pain--a comprehensive pathomorphological study of 546 cases. Gastroenterology (2008) 1.68
Oxygen, a source of life and stress. FEBS Lett (2007) 1.67
Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain (2011) 1.64
Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain (2005) 1.52
The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol (2012) 1.51
Tissue acidosis in nociception and pain. Prog Brain Res (1996) 1.48
Glutamate receptors and pain. Semin Cell Dev Biol (2006) 1.42
A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res (2005) 1.40
Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol (2008) 1.37
Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience (2010) 1.31
Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci (2008) 1.30
Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology (2011) 1.25
Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res (2000) 1.24
Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci (2010) 1.24
Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem (1996) 1.21
Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J Neurosci (2012) 1.21
Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J Med Chem (2005) 1.20
Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro. Am J Physiol (1992) 1.20
Regulation of glutathione levels in mouse spleen lymphocytes by transport of cysteine. J Cell Physiol (1987) 1.18
TEMPOL, a membrane-permeable radical scavenger, attenuates peroxynitrite- and superoxide anion-enhanced carrageenan-induced paw edema and hyperalgesia: a key role for superoxide anion. Eur J Pharmacol (2006) 1.17
Pathophysiology of cancer-associated hypercalcemia. Semin Oncol (1990) 1.13
Identification of acid-sensing ion channels in bone. Biochem Biophys Res Commun (2005) 1.13
Antioxidants attenuate multiple phases of formalin-induced nociceptive response in mice. Behav Brain Res (2006) 1.12
An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats. Neuroreport (1998) 1.11
Distinct ASIC currents are expressed in rat putative nociceptors and are modulated by nerve injury. J Physiol (2006) 1.10
Treatment of trigeminal ganglion neurons in vitro with NGF, GDNF or BDNF: effects on neuronal survival, neurochemical properties and TRPV1-mediated neuropeptide secretion. BMC Neurosci (2005) 1.07
Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs (2001) 1.07
Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J Pain (2011) 1.06
Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev (1993) 1.04
The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone (2010) 1.04
Heat and mechanical hyperalgesia in mice model of cancer pain. Pain (2005) 1.03
Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain. Mol Pain (2010) 1.03
Development of an in vivo model of human multiple myeloma bone disease. Blood (1996) 1.00
Metabotropic glutamate receptors and the control of chronic pain. Curr Opin Pharmacol (2011) 1.00
Osteoid osteoma: the uniquely innervated bone tumor. Mod Pathol (1998) 0.99
Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun (2009) 0.99
Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis. Hybridoma (2000) 0.99
Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. Cell Cycle (2011) 0.99
Intrathecal injection of metabotropic glutamate receptor subtype 3 and 5 agonist/antagonist attenuates bone cancer pain by inhibition of spinal astrocyte activation in a mouse model. Anesthesiology (2012) 0.98
Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab (2007) 0.97
Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCε pathway in dorsal root ganglion neurons. Mol Pain (2010) 0.97
Nitration is a mechanism of regulation of the NMDA receptor function during hypoxia. Neuroscience (2002) 0.96
Antinociceptive effect of CNS peroxynitrite scavenger in a mouse model of orofacial pain. Exp Brain Res (2007) 0.95
Targeting peroxynitrite driven nitroxidative stress with synzymes: A novel therapeutic approach in chronic pain management. Life Sci (2009) 0.93
Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice. Life Sci (2007) 0.93
Reactive nitroxidative species and nociceptive processing: determining the roles for nitric oxide, superoxide, and peroxynitrite in pain. Amino Acids (2010) 0.93
Evoked pain behavior and spinal glia activation is dependent on tumor necrosis factor receptor 1 and 2 in a mouse model of bone cancer pain. Neuroscience (2010) 0.92
Transient receptor potential vanilloid type 1 and pain development. Curr Opin Pharmacol (2011) 0.91
NOXious signaling in pain processing. Pharmacol Ther (2012) 0.90
Involvement of TRPV1 in nociceptive behavior in a rat model of cancer pain. J Pain (2008) 0.90
Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy. J Clin Oncol (2010) 0.89
Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res (2013) 0.89
Glutamate signaling in healthy and diseased bone. Front Endocrinol (Lausanne) (2012) 0.88
Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice. Arthritis Res Ther (2012) 0.87
Brain-derived neurotrophic factor modulates N-methyl-D-aspartate receptor activation in a rat model of cancer-induced bone pain. J Neurosci Res (2012) 0.86
Retooling manganese(III) porphyrin-based peroxynitrite decomposition catalysts for selectivity and oral activity: a potential new strategy for treating chronic pain. J Med Chem (2011) 0.86
Supraspinal peroxynitrite modulates pain signaling by suppressing the endogenous opioid pathway. J Neurosci (2012) 0.86
Distribution of selenium and oxidative stress in breast tumor-bearing mice. Nutrients (2013) 0.86
Involvement of CX3CR1 in bone cancer pain through the activation of microglia p38 MAPK pathway in the spinal cord. Brain Res (2012) 0.86
Effects of selective spinal nerve ligation on acetic acid-induced nociceptive responses and ASIC3 immunoreactivity in the rat dorsal root ganglion. Brain Res (2008) 0.85
Secretion of MCP-1 and other paracrine factors in a novel tumor-bone coculture model. BMC Cancer (2009) 0.85
The glutamatergic system as a target for neuropathic pain relief. Exp Physiol (2012) 0.85
Neuropeptide- and tyrosine hydroxylase-immunoreactive nerve fibers in painful Morton's neuromas. Muscle Nerve (2000) 0.84
Extracellular glutamate alters mature osteoclast and osteoblast functions. Can J Physiol Pharmacol (2010) 0.84
Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells. Biochem Pharmacol (2012) 0.84
Involvement of spinal monocyte chemoattractant protein-1 (MCP-1) in cancer-induced bone pain in rats. Neurosci Lett (2012) 0.83
CAT-1-mediated arginine uptake and regulation of nitric oxide synthases for the survival of human breast cancer cell lines. J Cell Biochem (2011) 0.83
Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model. Mol Pain (2010) 0.82
Distinct potassium channels on pain-sensing neurons. Proc Natl Acad Sci U S A (2001) 1.90
Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J Pharmacol Exp Ther (2006) 1.75
Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor. J Neurosci (2001) 1.72
Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci (2001) 1.67
Glial cell line-derived neurotrophic factor normalizes neurochemical changes in injured dorsal root ganglion neurons and prevents the expression of experimental neuropathic pain. Neuroscience (2003) 1.35
Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Br J Pharmacol (2010) 1.30
Opioid receptor types and subtypes: the delta receptor as a model. Annu Rev Pharmacol Toxicol (1996) 1.28
Neuropathic pain: the paradox of dynorphin. Mol Interv (2001) 1.27
The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology (2001) 1.24
Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sci (2003) 1.24
Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain (1997) 1.18
Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J Neurosci (2003) 1.11
Differential activities of intrathecal MK-801 or morphine to alter responses to thermal and mechanical stimuli in normal or nerve-injured rats. Pain (1997) 1.09
Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience (2003) 0.91
delta-Opioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice. Eur J Pharmacol (2000) 0.88
Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. J Pharmacol Exp Ther (2013) 0.82
Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA. Br J Pharmacol (2010) 0.82
Melanocortinergic control of penile erection. Peptides (2005) 0.82
Inhibitory effects of anesthetics and ethanol on muscarinic receptors expressed in Xenopus oocytes. Eur J Pharmacol (1997) 0.81
Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats. J Neurosci Methods (2011) 0.80
Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist. J Pharmacol Exp Ther (2006) 0.79
Dynorphin-independent spinal cannabinoid antinociception. Pain (2002) 0.79
Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. Neuroreport (1996) 0.78
The role of the G protein gamma(2) subunit in opioid antinociception in mice. Eur J Pharmacol (2000) 0.76